{"pre_text": ["hologic , inc .", "notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) a new platform technology to analyze images and breast density measurement .", "the projects were substantially completed as planned in fiscal 2007 .", "the deferred income tax asset relates to the tax effect of acquired net operating loss carry forwards that the company believes are realizable partially offset by acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes .", "acquisition of suros surgical systems , inc .", "on july 27 , 2006 , the company completed the acquisition of suros surgical systems , inc .", "( 201csuros 201d ) , pursuant to an agreement and plan of merger dated april 17 , 2006 .", "the results of operations for suros have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its mammography/breast care business segment .", "suros , located in indianapolis , indiana , develops , manufactures and sells minimally invasive interventional breast biopsy technology and products for biopsy , tissue removal and biopsy site marking .", "the initial aggregate purchase price for suros of approximately $ 248100 ( subject to adjustment ) consisted of 4600 shares of hologic common stock valued at $ 106500 , cash paid of $ 139000 , and approximately $ 2600 for acquisition related fees and expenses .", "the company determined the fair value of the shares issued in connection with the acquisition in accordance with eitf issue no .", "99-12 , determination of the measurement date for the market price of acquirer securities issued in a purchase business combination .", "the components and allocation of the final purchase price , consists of the following approximate amounts: ."], "post_text": ["the acquisition also provides for a two-year earn out .", "the earn-out is payable in two annual cash installments equal to the incremental revenue growth in suros 2019 business in the two years following the closing .", "the company has considered the provision of eitf issue no .", "95-8 , accounting for contingent consideration paid to the shareholders of and acquired enterprise in a purchase business combination , and concluded that this contingent consideration represents additional purchase price .", "during the fourth quarter of fiscal 2007 the company paid approximately $ 19000 to former suros shareholders for the first annual earn-out period resulting in an increase to goodwill for the same amount .", "the company also accrued $ 24500 for the second and final earn-out related to suros 2019 incremental revenue growth during the fourth quarter of fiscal 2008 , with an increase to goodwill , of which $ 24400 had been paid as of september 27 , 2008 .", "in addition to the earn-out discussed above , the company decreased goodwill in the amount of $ 1300 during the year ended september 27 , 2008 and increased goodwill in the amount of $ 210 during the year ended september 29 , 2007 .", "the increase in 2007 was primarily related to recording a liability of approximately $ 550 in accordance with eitf 95-3 related to the termination of certain employees who have ceased all services for the company .", "approximately $ 400 of this liability was paid during the year ended september 29 , 2007 and the balance was paid during fiscal 2008 .", "this increase was partially offset by a decrease to goodwill as a result of a change in the valuation of certain assets and liabilities acquired based on information received during the year ended september 29 , 2007 .", "the decrease in goodwill during 2008 was related to the reduction of an income tax liability .", "there have been no other material changes to purchase price allocations. ."], "table": [["net tangible assets acquired as of july 27 2006", "$ 13100"], ["in-process research and development", "4900"], ["developed technology and know-how", "46000"], ["customer relationship", "17900"], ["trade name", "5800"], ["deferred income taxes", "-21300 ( 21300 )"], ["goodwill", "181700"], ["final purchase price", "$ 248100"]], "table_ori": [["Net tangible assets acquired as of July 27, 2006", "$13,100"], ["In-process research and development", "4,900"], ["Developed technology and know-how", "46,000"], ["Customer relationship", "17,900"], ["Trade name", "5,800"], ["Deferred income taxes", "(21,300)"], ["Goodwill", "181,700"], ["Final purchase price", "$248,100"]]}

Question: what is the estimated price of hologic common stock used in the acquisition of suros?
Evidence:
text_9: the initial aggregate purchase price for suros of approximately $ 248100 ( subject to adjustment ) consisted of 4600 shares of hologic common stock valued at $ 106500 , cash paid of $ 139000 , and approximately $ 2600 for acquisition related fees and expenses .
Program: divide(106500, 4600)
Answer:
str_answer: 23.2
exe_answer: 23.15217